These authors contributed equally to this study.
The effect of anti-CD40 ligand in immune thrombocytopenic purpura
Article first published online: 13 MAR 2008
© 2008 The Authors
British Journal of Haematology
Volume 141, Issue 4, pages 545–548, May 2008
How to Cite
Patel, V. L., Schwartz, J. and Bussel, J. B. (2008), The effect of anti-CD40 ligand in immune thrombocytopenic purpura. British Journal of Haematology, 141: 545–548. doi: 10.1111/j.1365-2141.2008.07039.x
- Issue published online: 27 MAR 2008
- Article first published online: 13 MAR 2008
- Received 17 September 2007; accepted for publication 29 November 2007
- platelet antibody;
- anti-CD40 ligand;
- activated CD4+ T cell
Immune thrombocytopenic purpura (ITP) is mediated by antiplatelet autoantibodies possibly involving CD40:CD40L co-stimulation. Two humanized anti-CD40L monoclonal antibodies, hu5c8 and IDEC-131, were evaluated in 46 patients with chronic refractory ITP. Fifteen patients were treated with 20 mg/kg of hu5c8: four (27%) had complete responses (CR) and two (13%) had partial responses (PR). Three responders to hu5c8 were successfully retreated with IDEC-131, demonstrating its efficacy. Thirty-one subsequent patients were treated with 5–20 mg/kg per infusion of IDEC-131: five (16%) responded (one CR and four PR). The 24% (11/46) overall response rate demonstrates the potential role of CD40-CD40L in the pathogenesis of ITP.